Current and historical daily PE Ratio for Shenzhen Salubris Pharmaceuticals Co Ltd (
SZSE:002294
) from 2009 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shenzhenlubris Pharmaceuticals stock (SZSE:002294) PE ratio as of Jun 10 2024 is 53.45.
More Details
Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) PE Ratio (TTM) Chart
Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 1201
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Shenzhenlubris Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-10 | 53.5 | 2024-04-01 | 57.8 |
| 2024-06-07 | 53.5 | 2024-03-29 | 57.1 |
| 2024-06-06 | 54.4 | 2024-03-28 | 56.6 |
| 2024-06-05 | 55.1 | 2024-03-27 | 53.7 |
| 2024-06-04 | 54.4 | 2024-03-26 | 52.6 |
| 2024-06-03 | 53.1 | 2024-03-25 | 52.1 |
| 2024-05-31 | 53.6 | 2024-03-22 | 53.3 |
| 2024-05-30 | 52.7 | 2024-03-21 | 54.7 |
| 2024-05-29 | 52.8 | 2024-03-20 | 54.2 |
| 2024-05-28 | 52.7 | 2024-03-19 | 54.6 |
| 2024-05-27 | 53.7 | 2024-03-18 | 56.3 |
| 2024-05-24 | 54.3 | 2024-03-15 | 56.4 |
| 2024-05-23 | 54.5 | 2024-03-14 | 54.4 |
| 2024-05-22 | 55.5 | 2024-03-13 | 52.9 |
| 2024-05-21 | 56.3 | 2024-03-12 | 53.4 |
| 2024-05-20 | 57.7 | 2024-03-11 | 53.4 |
| 2024-05-17 | 58.0 | 2024-03-08 | 52.7 |
| 2024-05-16 | 58.0 | 2024-03-07 | 52.3 |
| 2024-05-15 | 58.9 | 2024-03-06 | 53.6 |
| 2024-05-14 | 60.0 | 2024-03-05 | 55.3 |
| 2024-05-13 | 60.2 | 2024-03-04 | 55.8 |
| 2024-05-10 | 61.2 | 2024-03-01 | 55.4 |
| 2024-05-09 | 61.8 | 2024-02-29 | 56.1 |
| 2024-05-08 | 61.1 | 2024-02-28 | 55.0 |
| 2024-05-07 | 61.8 | 2024-02-27 | 55.6 |
| 2024-05-06 | 61.5 | 2024-02-26 | 55.0 |
| 2024-04-30 | 62.6 | 2024-02-23 | 54.8 |
| 2024-04-29 | 62.4 | 2024-02-22 | 55.7 |
| 2024-04-26 | 61.3 | 2024-02-21 | 55.7 |
| 2024-04-25 | 60.6 | 2024-02-20 | 56.5 |
| 2024-04-24 | 58.8 | 2024-02-19 | 56.9 |
| 2024-04-23 | 59.9 | 2024-02-08 | 59.5 |
| 2024-04-22 | 56.5 | 2024-02-07 | 58.2 |
| 2024-04-19 | 55.2 | 2024-02-06 | 52.9 |
| 2024-04-18 | 56.5 | 2024-02-05 | 48.1 |
| 2024-04-17 | 56.7 | 2024-02-02 | 48.4 |
| 2024-04-16 | 56.5 | 2024-02-01 | 49.8 |
| 2024-04-15 | 57.6 | 2024-01-31 | 49.9 |
| 2024-04-12 | 56.8 | 2024-01-30 | 51.7 |
| 2024-04-11 | 56.5 | 2024-01-29 | 53.3 |
| 2024-04-10 | 57.2 | 2024-01-26 | 53.6 |
| 2024-04-09 | 57.9 | 2024-01-25 | 55.6 |
| 2024-04-08 | 57.2 | 2024-01-24 | 53.4 |
| 2024-04-03 | 57.4 | 2024-01-23 | 53.2 |
| 2024-04-02 | 57.0 | 2024-01-22 | 52.7 |
Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Shenzhen Salubris Pharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000FW8
Share Class Description:
SZSE:002294: Class ACompare
Compare
Traded in other countries / regions
002294.China IPO Date
2009-09-10Description
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers